Kavita Subramaniam

I joined the Translational Research Office (TRO) as a Translational Research Manager in January 2023.

Prior to joining the TRO, I did my postdoctoral work with King's College London. The team and I worked on a translational gene therapy project called ‘SPRAYCOL’ to develop a new form of gene supplementation therapy for individuals suffering from a rare genetic skin disease - recessive dystrophic epidermolysis bullosa (RDEB). We were testing a patient-friendly, less-invasive gene therapy approach and a delivery system using a novel cell spray device to minimize patients' pain in collaboration with a biotechnology company, RenovaCare Inc. 

Before that, I did a postdoctoral project with the University of Oxford where I worked alongside Bayer Pharmaceuticals, as part of the Oxford-Bayer Alliance. We worked on a target discovery project on the role of vasculature in uterine fibroid-related heavy menstrual bleeding.

I did my PhD at the University of Malaya, Malaysia on the role of tumour microenvironment in endometrial cancer.